RxDoctor Payments DataLook up a doctor →

Luke Nordquist, MD

Hematology & Oncology · Omaha, NENPI 1538149414

Payments from drug & device makers

$29,263,496in general payments, 2019–2025

Across 3,346 payments — averaging $8745.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$7.7M
  • Medivation LLC.$5.7M
  • Novartis$4.2M
  • Bayer$3M
  • AstraZeneca$2.1M
  • Janssen Research & Development, LLC$1.9M
  • plus $4.8M from 31 others
$17,212in research payments, 2019–2025

Across 19 payments — averaging $905.88 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$11K
  • Novartis$4K
  • Novartis Pharma AG$2K
  • Astellas Pharma Global Development$466
  • Eli Lilly$44

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$29,263,496 in reported general payments places this provider in the 95th percentile of 73 hematology & oncology providers in Nebraska.

See all hematology & oncology providers in Nebraska

Medicare billing

Part B allowed, 2024
$4,302,898
Medicare patients
655
Services billed
88,294

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Omaha

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →